0
0
0
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
6/14/2024, 8:05 AM
Summary of Bill HJRES 145
Bill 118 hjres 145 is a piece of legislation that aims to disapprove of a rule submitted by the Food and Drug Administration (FDA) regarding "Medical Devices; Laboratory Developed Tests." The rule in question falls under chapter 8 of title 5, United States Code, which governs the regulatory process for federal agencies.
The bill seeks to exercise congressional oversight by disapproving of the FDA's rule, which likely means that Congress believes the rule is not in the best interest of the public or is not in line with congressional intent. The rule in question likely pertains to the regulation of laboratory developed tests, which are medical tests developed and performed within a single laboratory.
If this bill is passed, it would prevent the FDA from implementing the rule and would send a message that Congress does not support the FDA's approach to regulating laboratory developed tests. This could have significant implications for the FDA's ability to regulate medical devices and tests in the future. Overall, Bill 118 hjres 145 represents a significant moment in the ongoing debate over the regulation of medical devices and tests in the United States. It highlights the tension between congressional oversight and agency authority, and could have far-reaching implications for the FDA's regulatory powers.
The bill seeks to exercise congressional oversight by disapproving of the FDA's rule, which likely means that Congress believes the rule is not in the best interest of the public or is not in line with congressional intent. The rule in question likely pertains to the regulation of laboratory developed tests, which are medical tests developed and performed within a single laboratory.
If this bill is passed, it would prevent the FDA from implementing the rule and would send a message that Congress does not support the FDA's approach to regulating laboratory developed tests. This could have significant implications for the FDA's ability to regulate medical devices and tests in the future. Overall, Bill 118 hjres 145 represents a significant moment in the ongoing debate over the regulation of medical devices and tests in the United States. It highlights the tension between congressional oversight and agency authority, and could have far-reaching implications for the FDA's regulatory powers.
Read the Full Bill
Current Status of Bill HJRES 145
Bill HJRES 145 is currently in the status of Bill Introduced since May 16, 2024. Bill HJRES 145 was introduced during Congress 118 and was introduced to the House on May 16, 2024. Bill HJRES 145's most recent activity was Referred to the House Committee on Energy and Commerce. as of May 16, 2024
Bipartisan Support of Bill HJRES 145
Total Number of Sponsors
1Democrat Sponsors
0Republican Sponsors
1Unaffiliated Sponsors
0Total Number of Cosponsors
8Democrat Cosponsors
0Republican Cosponsors
8Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HJRES 145
Primary Policy Focus
HealthAlternate Title(s) of Bill HJRES 145
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Comments
Sponsors and Cosponsors of HJRES 145
Latest Bills
Honduras Expropriation Accountability Act
Bill HR 7807March 24, 2026
Debt-to-GDP Transparency and Stabilization Act
Bill HR 7808March 24, 2026
Responsible Containment Reauthorization Act
Bill HR 7811March 24, 2026
BLS Act
Bill HR 7804March 24, 2026
Direct File Act of 2026
Bill HR 7806March 24, 2026
Red Star Service Banner Act
Bill HR 7815March 24, 2026
Lowering Student Loans Act
Bill HR 7810March 24, 2026
HEALTHY BRAINS Act of 2026
Bill HR 7779March 24, 2026
Parity for Tribal Educators Act
Bill HR 7781March 24, 2026
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "Debt Collection Practices (Regulation F); Deceptive and Unfair Collection of Medical Debt".
Bill SJRES 141March 24, 2026
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Bill SJRES 82June 12, 2024




